Deadline: 25-Jan-22
The European Commission (EC) is offering Action Grants for Computer-aided Drug Repurposing for Cancer Therapy Project to identify potential viable effective anti-cancer drugs by making use and piloting ‘in-silico drug repurposing’ including by upscaling available innovation using advanced computing and the new big-data technologies and high-performance computing while reducing timeframes and development costs.
The action will launch an EU platform based on ‘computational drug networks’ to predict, in-silico, the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease biomarkers. This will be implemented following a time and cost-effective approach, also building on experiences with repurposing of medicines to treat COVID-19, where high-performance computing will be used to rapidly test existing molecules and new drug combinations.
Funding Information
- Available budget for this topic: EUR 3 000 000
- The duration of proposals should range between 12 and 36 months. Given the complexity of the activities to be funded under this topic, the recommended length of a project is 24-36 months.
Expected Impact
- The launch of an EU platform based on improved ‘computational drug networks’ is expected to result in a better prediction of the efficacy of approved drugs against relevant cancer targets, as well as to select better responder patients or disease biomarkers, and to link Member States’ structures responsible for cancer treatment and care.
- Starting with cancers with poor prognosis and rare cancers, and using high-performance computing, this work will help to improve the arsenal of anticancer drugs and overcome certain limitations of modern cancer therapies against old and new therapeutic targets in oncology.
- The action is likely to increase available anticancer drugs and overcome limitations of current cancer therapies against old and new therapeutic targets in oncology, to the final benefit of patients with poor prognosis and rare cancers.
Eligibility Criteria
In order to be eligible for funding, the applicants (beneficiaries and affiliated entities) must:
- be legal entities (public or private bodies) created under Union law or an international organisation, or
- be established in one of the eligible countries, i.e.:
- EU Member States (including overseas countries and territories linked to it (OCTs))
- eligible non-EU countries: EEA countries and countries associated to the EU4Health Programme (third countries, candidate countries and potential candidate countries, neighbourhood countries) or countries which are in ongoing negotiations for an association agreement and where the agreement enters into force before grant signature.
For more information, visit https://bit.ly/3Bn1SZk